Skip to content
sellWeak cluster of 610b5-1 plan

Mark Eisner sold $16k of VIR

EVP and Chief Medical Officer at Vir Biotechnology, Inc.. 2,089 shares at an average of $7.45, traded Feb 23, 2026, filed Feb 24, 2026.

Warning score
10
Value
$16k
2,089 shares
Holdings after
157,529
-1% from before
From 52-week low
+74%
low $4.28, close $7.43
From 52-week high
-22%
high $9.47, as of Feb 23, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $16k at market
    0
  • Share of holdings sold
    Sold 1.3% of holdings
    0
  • Cluster
    6 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

VIROct 9, 2026 · close 11.70
Since filing Feb 24, 2026: +23.3%SPY +14.2% · excess +9.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001628280-26-011329, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 22, 2026AGrant or award
Common Stock10b5-1
+55,000$0.00$0159,618Feb 24, 2026
Feb 23, 2026SOpen-market sale
Common Stock10b5-1
-2,089$7.45$16k157,529Feb 24, 2026
Feb 22, 2026AGrant or award
Stock Option (Right to Buy)derivative10b5-1
+110,000$0.00$0110,000Feb 24, 2026

Related signals

Other insiders at Vir Biotechnology, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
33Weak
VIRsell 210b5-1
Vir Biotechnology, Inc.
Marianne De Backer
President and CEO
$664k
72,559 shares
-7%
16Weak
VIRsell 210b5-1
Vir Biotechnology, Inc.
Brent Sabatini
SVP, Chief Accounting Officer
$70k
7,711 shares
-11%
22Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Vicki L Sato
director
$209k
22,000 shares
-2%
31Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Marianne De Backer
Chief Executive Officer
$141k
14,762 shares
-1%
16Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Mark Eisner
EVP and Chief Medical Officer
$34k
3,505 shares
-2%
17Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Jason O'Byrne
EVP & Chief Financial Officer
$16k
1,634 shares
-1%
11Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Vicki L Sato
director
$413k
42,377 shares
-4%
10Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Brent Sabatini
SVP, Chief Accounting Officer
$14k
1,430 shares
-2%
26Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Vanina de Verneuil
EVP, General Counsel, Corp Sec
$164k
16,817 shares
-13%
31Weak
VIRsell 610b5-1
Vir Biotechnology, Inc.
Marianne De Backer
Chief Executive Officer
$142k
19,039 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.